Multiple cycles of high-dose doxorubicin and cyclophosphamide with G- CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer

Annals of Oncology

Volumn 8, Issue 10, 1997, Pages 957-962

  Honkoop, A H ^a   Van Der Wall, E ^a   Feller, N ^a   Schuurhuis, G J ^a   Van Der Vijgh, W J F ^a   Boven, E ^a   Van Groeningen, C J ^a   Giaccone, G ^a   Hoekman, K ^a   Vermorken, J B ^a   Wagstaff, J ^a   Pinedo, H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; High dose chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANTINEOPLASTIC ACTIVITY; APHERESIS; ARTICLE; BREAST CANCER; CANCER REGRESSION; CLINICAL ARTICLE; COLONY FORMING UNIT; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HEMATOPOIETIC STEM CELL; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; MAXIMUM ALLOWABLE CONCENTRATION; METASTASIS; MUCOSA INFLAMMATION; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLONY-FORMING UNITS ASSAY; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED;

EID: 9844229901     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008259518263     Document Type: Article

References (22)

1. Frei III E, Canellos G. Dose: A Critical Factor in Cancer Chemotherapy. Am J Med 1980; 69: 585-94.
2. Kent Osborne C. Dose intensity as a therapeutic strategy in breast cancer; Breast Cancer Res Treat 1991; 20: S11-4.
3. Honkoop AH, Hoekman K, Wagstaff J et al. Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. Ann Oncol 1996; 7: 35-9.
4. Honkoop AH, Hoekman K, Wagstaff J et al. Continuous infusion or subcutaneous injection of granulocyte-macrophage colony stimulating factor; increased efficacy and reduced toxicity when given subcutaneously. Br J Cancer 1996; 74: 1132-6.
5. Honkoop AH, Pinedo HM. High dose chemotherapy in the treat4 ment of breast cancer (Review). Intern J Oncol 1995; 6: 911-8.
6. Antman KH. Dose-intensive therapy in breast cancer. In Armitage JO, Antman KH (eds): High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Baltimore, MD: Williams and Wilkins 1992; 701-18.
7. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993; 85: 632-9.
8. Holland JF. Breaking the cure barrier. J Clin Oncol 1993; 1: 75-80.
9. Smith EI, Evans BD, Harland SJ et al. Autologous bone marrow rescue is unnecessary after high-dose cyclophosphamide. Lancet 1983; 1: 76-7.
10. Vantongelen K (eds). A Practical Guide to EORTC Studies. Brussels: EORTC Central Office-Data Center 1994.
11. Eder RP, Elias AD, Ayash L et al. Phase I trial of continuousinfusion cyclophosphamide in refractory cancer patients. Cancer Chemother Pharmacol 1991; 29: 61-5.
12. Mross K, Maessen P, Vijgh WJF van der et al. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988; 6: 517-26.
13. O'Flaherty E, Sparrow R, Szer J. Bone marrow function from patients after bone marrow transplantation. Bone Marrow Transplant 1995; 15: 207-12.
14. Novitzky N, Mohamed R. Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation. Exp Hematol 1995; 23: 1661-6.
15. Somlo G, Doroshow JH, Forman SJ et al. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer 1994; 73: 1678-85.
16. Gianni AM, Bregni M, Siena S et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768-78.
17. Smith IE, Evans BD, Harland SJ et al. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemother Pharmacol 1985; 14: 120-4.
18. Chen TL, Passos-Coelho JL, Noe DA et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995; 55: 810-6.
19. Meagher RC, Herzig RH. Techniques of harvesting and cryo-preservation of stem cells. Hematol Oncol Clinics 1993; 37: 501-33.
20. Bolwell BJ, Fishleder A, Andresen SW et al. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: Parameters of bone marrow engraftment. Bone Marrow Tranplant 1993; 12: 609-14.
21. Basser RL, To LB, Begley CG et al. Adjuvant treatment of high risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Clin Cancer Res 1995; 1: 715-21.
22. Bezwoda WR, Dansey R, Seymour L et al. Non-cryopreserved, limited number (1 or 2) of peripheral blood progenitor cell (PBPC) collections following G-CSF administration provide adequate hematologic support for high dose chemotherapy. Hematol Oncol 1994; 12: 101-10.